These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32868381)

  • 1. Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
    Bellmunt J; Kim J; Reardon B; Perera-Bel J; Orsola A; Rodriguez-Vida A; Wankowicz SA; Bowden M; Barletta JA; Morote J; de Torres I; Juanpere N; Lloreta-Trull J; Hernandez S; Mouw KW; Taplin ME; Cejas P; Long HW; Van Allen EM; Getz G; Kwiatkowski DJ
    Cancer Res; 2020 Oct; 80(20):4476-4486. PubMed ID: 32868381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
    Kim PH; Cha EK; Sfakianos JP; Iyer G; Zabor EC; Scott SN; Ostrovnaya I; Ramirez R; Sun A; Shah R; Yee AM; Reuter VE; Bajorin DF; Rosenberg JE; Schultz N; Berger MF; Al-Ahmadie HA; Solit DB; Bochner BH
    Eur Urol; 2015 Feb; 67(2):198-201. PubMed ID: 25092538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
    Kamran SC; Zhou Y; Otani K; Drumm M; Otani Y; Wu S; Wu CL; Feldman AS; Wszolek M; Lee RJ; Saylor PJ; Lennerz J; Van Allen E; Willers H; Hong TS; Liu Y; Davicioni E; Gibb EA; Shipley WU; Mouw KW; Efstathiou JA; Miyamoto DT
    Clin Cancer Res; 2023 Dec; 29(24):5116-5127. PubMed ID: 37870965
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Li Q; Damish AW; Frazier Z; Liu D; Reznichenko E; Kamburov A; Bell A; Zhao H; Jordan EJ; Gao SP; Ma J; Abbosh PH; Bellmunt J; Plimack ER; Lazaro JB; Solit DB; Bajorin D; Rosenberg JE; D'Andrea AD; Riaz N; Van Allen EM; Iyer G; Mouw KW
    Clin Cancer Res; 2019 Feb; 25(3):977-988. PubMed ID: 29980530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
    Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
    BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic characterization of response to chemoradiation in urothelial bladder cancer.
    Desai NB; Scott SN; Zabor EC; Cha EK; Hreiki J; Sfakianos JP; Ramirez R; Bagrodia A; Rosenberg JE; Bajorin DF; Berger MF; Bochner BH; Zelefsky MJ; Kollmeier MA; Ostrovnaya I; Al-Ahmadie HA; Solit DB; Iyer G
    Cancer; 2016 Dec; 122(23):3715-3723. PubMed ID: 27479538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
    Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
    Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors.
    Koutros S; Rao N; Moore LE; Nickerson ML; Lee D; Zhu B; Pardo LA; Baris D; Schwenn M; Johnson A; Jones K; Garcia-Closas M; Prokunina-Olsson L; Silverman DT; Rothman N; Dean M
    Clin Cancer Res; 2021 Jul; 27(13):3725-3733. PubMed ID: 33849962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.
    Kim J; Mouw KW; Polak P; Braunstein LZ; Kamburov A; Kwiatkowski DJ; Rosenberg JE; Van Allen EM; D'Andrea A; Getz G
    Nat Genet; 2016 Jun; 48(6):600-606. PubMed ID: 27111033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
    Mossanen M; Carvalho FLF; Muralidhar V; Preston MA; Reardon B; Conway JR; Curran C; Freeman D; Sha S; Sonpavde G; Hirsch M; Kibel AS; Van Allen EM; Mouw KW
    Eur Urol; 2022 May; 81(5):466-473. PubMed ID: 34953602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival.
    Yap KL; Kiyotani K; Tamura K; Antic T; Jang M; Montoya M; Campanile A; Yew PY; Ganshert C; Fujioka T; Steinberg GD; O'Donnell PH; Nakamura Y
    Clin Cancer Res; 2014 Dec; 20(24):6605-17. PubMed ID: 25316812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
    Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
    J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma.
    Wang Q; Bai J; Abliz A; Liu Y; Gong K; Li J; Shi W; Pan Y; Liu F; Lai S; Yang H; Lu C; Zhang L; Chen W; Xu R; Cai H; Ke Y; Zeng C
    Genomics Proteomics Bioinformatics; 2015 Aug; 13(4):258-70. PubMed ID: 26386145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
    Gerald T; Margulis V; Meng X; Bagrodia A; Cole S; Qin Q; Call SG; Mauer E; Lotan Y; Woldu SL
    Urol Oncol; 2023 Mar; 41(3):148.e17-148.e24. PubMed ID: 36653279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight.
    Hurst CD; Cheng G; Platt FM; Castro MAA; Marzouka NS; Eriksson P; Black EVI; Alder O; Lawson ARJ; Lindskrog SV; Burns JE; Jain S; Roulson JA; Brown JC; Koster J; Robertson AG; Martincorena I; Dyrskjøt L; Höglund M; Knowles MA
    Cell Rep Med; 2021 Dec; 2(12):100472. PubMed ID: 35028613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis.
    de Jong JJ; Valderrama BP; Perera J; Juanpere N; Cejas P; Long H; Albà MM; Gibb EA; Bellmunt J
    Br J Cancer; 2022 Jul; 127(2):313-320. PubMed ID: 35449454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
    Shi MJ; Meng XY; Fontugne J; Chen CL; Radvanyi F; Bernard-Pierrot I
    Genome Med; 2020 Sep; 12(1):85. PubMed ID: 32988402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India.
    Gangawar R; Ahirwar D; Mandhani A; Mittal RD
    Med Oncol; 2010 Jun; 27(2):159-66. PubMed ID: 19242824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.